All News

Found 553 articles

• Incyte Corporation Earns $25 Million Milestone As Jakavi® (ruxolitinib) Recommended For Approval In Europe For Polycythemia Vera

  1/23/2015

• Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells, Cellular Dynamics

  12/24/2014

• Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting

  12/9/2014

• Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition

  12/8/2014

• FDA Approves Incyte Corporation's Jakafi For Patients With Polycythemia Vera

  12/5/2014

• Galena Biopharma Receives Notice Of Allowance Of U.S. Patent Application For GALE-401 (Anagrelide Controlled Release) Composition Of Matter

  12/2/2014

• Galena Biopharma To Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition

  12/1/2014

• Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

  11/18/2014

• Promedior Receives Fast Track Designation For PRM-151 For The Treatment Of Myelofibrosis

  11/3/2014

• Galena Biopharma Doses First Patient In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

  9/9/2014

• Galena Biopharma Reports Second Quarter 2014 Results

  8/12/2014

• Geron Corporation Reports Second Quarter 2014 Financial Results

  8/11/2014

• Incyte Corporation's Jakafi Fails to Provide RELIEF In Phase 3 Trial

  7/28/2014

• Tiny Promedior To Present Positive Phase 2 Myelofibrosis Data Next Week

  5/30/2014

• American Society of Clinical Oncology 2014: Boehringer Ingelheim Pharmaceuticals, Inc. To Present Its Latest Oncology Research Including New Data For Gilotrif® (afatinib) In Advanced Lung Cancer Patients

  5/30/2014

• Positive Results Presented From Proof-Of-Concept Phase 2 Clinical Trial Of Incyte Corporation's Oral JAK1 Inhibitor In Patients With Myelofibrosis

  12/10/2013

• GIOTRIF® (afatinib) Approved by Health Canada as a Treatment for Patients With Metastatic Adenocarcinoma of the Lung With Activating EGFR Mutation(s) Who Are Tyrosine Kinase Inhibitor Naive

  11/8/2013

• AOP Orphan Pharmaceuticals AG Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera

  10/10/2013

• Incyte Corporation Surges on Positive Phase 2 Pancreatic Cancer Data; Stock Rockets +33.48% Wednesday, August 21, 2013 at Market Close

  8/23/2013

• Novartis AG Shares New Findings With 170 Abstracts at American Society of Clinical Oncology and European Hematology Association

  5/30/2013